Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVXUR0)

• Drug Name: Magrolimab Drug Info
• Synonyms: GS-4721

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 3	[1]
Myelodysplastic syndrome	2A37	Phase 3	[2]

• Cross-matching ID: TTD Drug ID: DMVXUR0

Molecule-Related Drug Atlas

Drug(s) Targeting T-cell surface glycoprotein CD4 (CD4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibalizumab	DMV67QO	Human immunodeficiency virus infection	1C62	Approved	[4]
TNX-355	DMYA41S	Human immunodeficiency virus infection	1C62	Phase 3	[5]
Zanolimumab	DMKB4ZY	Lymphoma	2A80-2A86	Phase 3	[6]
Fluoropeptide vaccine	DMCEUOH	Influenza virus infection	1E30-1E32	Phase 2	[7]
BT-061	DM2LZIY	Asthma	CA23	Phase 2	[8]
LIPO-4	DMJRALD	Human immunodeficiency virus infection	1C62	Phase 1	[9]
Combinectin	DMTLP1N	Human immunodeficiency virus infection	1C62	Phase 1	[10]
TMB-365	DMH3E5C	Human immunodeficiency virus-1 infection	1C62	Phase 1	[11]
CD4CAR	DM09SW6	T-cell leukaemia	2A90	Phase 1	[12]
VRC07-523LS	DM0S9OT	Human immunodeficiency virus-1 infection	1C62	Phase 1	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
T-cell surface glycoprotein CD4 (CD4)	TTN2JFW	CD4_HUMAN	Inhibitor	[3]

References

• [1] ClinicalTrials.gov (NCT04778397) Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia (ENHANCE-2). U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04313881) Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE). U.S. National Institutes of Health.
• [3] Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021 Jul;48:100791.
• [4] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [5] Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94.
• [6] Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007 Jun 1;109(11):4655-62.
• [7] A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine. 2015 Jan 3;33(2):396-402.
• [8] Tregalizumab (BT-061) increases regulatory T cell function. Boosting regulatory T-cell function with the humanized CD4-specific humanized monoclonal antibody Tregalizumab (BT-061). Immunol Cell Biol.2015 Apr;93(4):321-2.
• [9] Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013 Sep 13;31(40):4406-15.
• [10] Clinical pipeline report, company report or official report of ViiV Healthcare.
• [11] Clinical pipeline report, company report or official report of TaiMed Biologics.
• [12] Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
• [13] Clinical pipeline report, company report or official report of TaiMed Biologics.